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Pcute Changes in Circulating Natriuretic
eptide Levels in Relation to Myocardial Ischemia
arc S. Sabatine, MD, MPH,* David A. Morrow, MD, MPH, FACC,* James A. de Lemos, MD, FACC,†
orbjorn Omland, MD,‡ Milind Y. Desai, MD,§ Milenko Tanasijevic, MD, MBA,
hristian Hall, MD, PHD, FACC,¶ Carolyn H. McCabe, BS,* Eugene Braunwald, MD, FACC*
oston, Massachusetts; Dallas, Texas; Oslo, Norway; and Baltimore, Maryland
OBJECTIVES The aim of this study was to determine the effect of transient myocardial ischemia on
circulating natriuretic peptide levels.
BACKGROUND Natriuretic peptides are released by the heart in response to wall stress. We hypothesized that
transient myocardial ischemia would cause acute changes in circulating natriuretic peptide
levels.
METHODS B-type natriuretic peptide (BNP), N-terminal fragment of BNP pro-hormone (NT-pro-
BNP), and N-terminal fragment of atrial natriuretic peptide pro-hormone (NT-pro-ANP)
levels were measured in 112 patients before, immediately after, and 4 h after exercise testing
with nuclear perfusion imaging.
RESULTS Baseline levels of BNP were associated with the subsequent severity of provoked ischemia,
with median levels of 43, 62, and 101 pg/ml in patients with none, mild-to-moderate, and
severe inducible ischemia, respectively (p  0.03). Immediately after exercise, the median
increase in BNP was 14.2 pg/ml in patients with mild-to-moderate ischemia (p  0.0005)
and 23.7 pg/ml in those with severe ischemia (p  0.017). In contrast, BNP levels only rose
by 2.3 pg/ml in those who did not develop ischemia (p  0.31). A similar relationship was
seen between baseline NT-pro-BNP levels and inducible ischemia, but the changes in
response to ischemia were less pronounced. NT-pro-ANP levels rose with exercise in both
ischemic and non-ischemic patients. When added to traditional clinical predictors of
ischemia, a post-stress test BNP 80 pg/ml remained a strong and independent predictor of
inducible myocardial ischemia (odds ratio 3.0, p  0.025).
CONCLUSIONS Transient myocardial ischemia was associated with an immediate rise in circulating BNP
levels, and the magnitude of rise was proportional to the severity of ischemia. These findings
demonstrate an important link between the severity of an acute ischemic insult and the
circulating levels of BNP. (J Am Coll Cardiol 2004;44:1988–95) © 2004 by the American
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.07.057College of Cardiology Foundation
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satriuretic peptides are vasoactive hormones secreted by the
eart. Atrial natriuretic peptide (ANP) and B-type natri-
retic peptide (BNP) are synthesized as pro-hormones and
leaved by peptidases into the C-terminal active hormones
nd the N-terminal pro-hormone fragments (1). BNP in
articular has been shown to be a powerful diagnostic and
rognostic marker in heart failure (2,3). More recently,
NP has been studied in acute coronary syndromes. In
T-segment elevation myocardial infarction (MI), BNP
ises substantially and rapidly, with elevated levels apparent
n presentation and peak concentrations occurring by 16 h
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ccepted July 28, 2004.4). Elevated levels of BNP can also be detected in a subset
f patients presenting with non–ST-segment elevation
cute coronary syndromes (5), even in those without bio-
hemical evidence of myocardial necrosis or clinical evi-
ence of heart failure (6).
Given that the primary stimulus for natriuretic peptide
ecretion is increased myocardial wall stress, circulating
evels of these short-lived hormones might provide insight
nto transient changes in ventricular systolic and diastolic
unction during acute myocardial ischemia, which can
mpair both myocardial relaxation and contractility. There-
ore, we hypothesized that small but demonstrable amounts
f natriuretic peptides would be released in response to
ransient myocardial ischemia. We tested this hypothesis by
xamining circulating BNP, N-terminal fragment of BNP
ro-hormone (NT-pro-BNP), and N-terminal fragment of
NP pro-hormone (NT-pro-ANP) levels before and after
xercise stress testing and correlating the results with scin-
igraphic evidence of inducible ischemia.
ETHODS
atients. A total of 155 patients who were undergoing
tress testing with myocardial perfusion imaging at Brigham
nd Women’s Hospital were enrolled in PROtein Markers
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November 16, 2004:1988–95 Acute Changes in BNP With Myocardial Ischemiaf ischemia using Proteomic Testing (PROMPT)-
hrombolysis In Myocardial Infarction (TIMI) 35, a pro-
pective cohort study. The Human Research Committee
pproved the study protocol, and all patients provided
ritten informed consent. All patients who were referred for
tress testing for the evaluation of possible myocardial
schemia were eligible for participation. Patients who un-
erwent pharmacologic or submaximal exercise stress test-
ng (n  41) or those in whom adequate perfusion images
ere not obtained (n  2) were excluded, leaving a total of
12 patients included in these analyses.
tudy protocol. Data were obtained on each patient’s age,
ender, race, weight, cardiac risk factors (including hyper-
ension, diabetes mellitus, smoking, and hyperlipidemia),
revious cardiac disease (including angina, MI, congestive
eart failure [CHF], angiographically confirmed significant
oronary artery disease [CAD], percutaneous coronary in-
ervention, and coronary artery bypass grafting [CABG]),
nd cardiac medications.
Patients underwent exercise testing using the standard
ruce protocol. Duration of the stress test, metabolic
quivalents achieved, peak heart rate, and peak blood
ressure were recorded. If the patient developed angina
uring the test, the timing, quality (typical vs. atypical), and
ffect on the test (limiting or non-limiting) were noted. The
aximal horizontal or downsloping ST-segment changes
ere recorded in each electrocardiogram lead.
ingle-photon emission computed tomography myocar-
ial perfusion imaging. 99Tc tetrofosmin was adminis-
ered at peak stress, and imaging was performed soon
hereafter. Four hours later, a second injection was admin-
stered and repeat imaging was performed. A 20-segment
yocardial model was used for semiquantitative analysis,
ith a visual perfusion rating of 0 to 4 for each segment by
uclear cardiologists unaware of biomarker data. Quantita-
ive analysis of perfusion was also performed using the
Equal method to calculate the percent reversible and fixed
erfusion defects. Patients were categorized as having none
no reversible perfusion defects), mild-to-moderate (change
Abbreviations and Acronyms
ANP  atrial natriuretic peptide
BNP  B-type natriuretic peptide
CABG  coronary artery bypass graft
CAD  coronary artery disease
CHF  congestive heart failure
CI  confidence interval
LV  left ventricular
MI  myocardial infarction
NT-pro-ANP  N-terminal fragment of ANP
pro-hormone
NT-pro-BNP  N-terminal fragment of BNP
pro-hormone
OR  odds ration visual scale score of 1 to 10 points), or severe ischemia tchange in visual scale score of 10 points or a change of
5 points and a reversible defect percentage of 10%).
Blood samples were obtained immediately before, imme-
iately after (median 7 min), and 4 h after stress testing.
lood samples were placed on ice and processed within 60
in. Plasma was stored at80°C, and aliquots were thawed
or these analyses.
iomarkers. An established sequential sandwich immuno-
ssay (Biosite, Inc., San Diego, California) was used for the
uantification of BNP (5,6). The minimal detectable con-
entration is 4 pg/ml. The coefficient of variation is 5.0% at
3.8 pg/ml. NT-pro-BNP was measured on the Elecsys
010 (Roche Diagnostics, Basel, Switzerland). The minimal
etectable concentration is 50 pg/ml, and the coefficient of
ariation is 5.7% at 64 pg/ml. NT-pro-ANP was measured
sing a competitive-binding radioimmunoassay (7). The
inimal detectable concentration is 100 pmol/l, and the
oefficient of variation is 7.5% at 425 pmol/l. All assays were
erformed by personnel who had no knowledge of stress test
esults.
tatistical analyses. Patients were categorized for the pri-
ary analysis on the basis of the severity of ischemia as
etermined by myocardial perfusion imaging. Median na-
riuretic peptide levels at each time point were compared
cross groups using a non-parametric test for trend across
rdered groups (Jonckheere-Terpstra test) (8). The median
ifferences between baseline and post-stress test natriuretic
eptide levels were compared using signed rank tests. To
djust for differences in baseline factors, linear regression
as used after confirming that the residuals in such models
ere approximately normally distributed. Covariates in the
odel included age; gender; a history of hypertension;
revious MI, CABG, or CHF; use of beta-blockers, ni-
rates, angiotensin-converting enzyme inhibitors, angioten-
in receptor blockers, or digoxin; exercise duration and
ercent of maximal predicted heart rate that was achieved;
nd low ejection fraction. BNP was also considered as a
ategorical variable using a prespecified threshold of 80
g/ml (based on previous work) (5,6). The independent
alue of BNP for predicting ischemia was calculated using a
ultivariable logistic regression model that contained BNP
80 pg/ml plus additional covariates from the Duke tread-
ill score including exercise time, the presence of angina
non-limiting or limiting), and the magnitude of ST-
egment depression (0, 1, or 2 mm), as well as using a model
hat contained the aforementioned covariates plus age,
ender, cardiac risk factors (hypertension, diabetes, hyper-
holesterolemia, and smoking), and previous cardiac disease
nd procedures (angina, documented significant coronary
rtery stenosis, previous MI, percutaneous coronary inter-
ention, CABG, and CHF).
ESULTS
aseline characteristics. The baseline characteristics of
he 112 study participants are shown in Table 1. The mean
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Acute Changes in BNP With Myocardial Ischemia November 16, 2004:1988–95ge was 63 years. Seventy-five percent of patients were male,
4% had hypertension, 57% had known CAD, 49% had a
revious MI, 36% had undergone a percutaneous coronary
ntervention, 23% had undergone CABG, and 14% had a
istory of heart failure. The majority of patients were taking
spirin, beta-blockers, and hypolipidemics. One-quarter to
ne-third of patients were taking nitrates, calcium channel
lockers, angiotensin-converting enzyme inhibitors, and
iuretics.
xercise testing. Mean exercise duration was 7.4  2.9
in, maximum workload achieved was 8.7  3.1 metabolic
quivalents, and percent of maximum predicted heart rate
as 81  12%. Twenty-two percent of patients had
on-limiting angina and 9% had limiting angina. Horizon-
al or downsloping ST depression1 mm developed in 30%
f patients and 2 mm in 15% of patients. Forty percent of
atients had no inducible ischemia, 46% had mild-to-
oderate inducible ischemia, and 13% had severe ischemia.
he mean left ventricular (LV) ejection fraction was 55 
3%. Twenty-eight percent of patients had a LV ejection
raction 50%.
atriuretic peptide levels before and after stress test-
ng. Circulating plasma BNP levels immediately before,
mmediately after, and 4 h after stress testing are shown in
igure 1. In patients without demonstrable inducible isch-
mia, median BNP levels were low at baseline (43 pg/ml)
nd were not significantly changed immediately after stress
esting (49 pg ml) or at 4 h (40 pg/ml). In contrast, BNP
evels rose significantly immediately after exercise in patients
able 1. Patient Characteristics (n  112)
emographics
Age (yrs) 63 11
Male 84 (75%)
White 87 (78%)
ardiac risk factors
Hypertension 83 (74%)
Diabetes 27 (24%)
Current or former smoker 73 (65%)
Hyperlipidemia 83 (74%)
ardiac disease
Documented CAD 63 (57%)
Previous MI 55 (49%)
Previous PCI 40 (36%)
Previous CABG 26 (23%)
Previous CHF 16 (14%)
ardiac medications
Aspirin 93 (83%)
Beta-blocker 94 (84%)
Nitrates 23 (21%)
Calcium channel blocker 25 (22%)
ACE inhibitor 41 (37%)
Angiotensin receptor blocker 5 (4%)
Hypolipidemic 79 (71%)
Diuretic 33 (29%)
Digoxin 7 (6%)
ata are presented as mean values  SD or number (%) of patients.
ACE  angiotensin-converting enzyme; CABG  coronary artery bypass graft;
AD  coronary artery disease; CHF  congestive heart failure; MI  myocardial
nfarction; PCI  percutaneous coronary intervention.ith inducible ischemia. Among patients with mild-to- toderate ischemia, median BNP levels rose from 62 to 92
g/ml (p  0.0005). By 4 h, levels had returned close to
aseline (70 pg ml). Among patients with severe ischemia,
edian BNP levels were high at baseline at 101 pg/ml and
ose even higher after stress testing to 123 pg/ml (p 
.017). By 4 h after stress testing, BNP levels remained
levated at 115 pg/ml but were trending toward baseline
evels.
Levels of NT-pro-BNP are shown in Figure 2. In
atients without demonstrable inducible ischemia, median
T-pro-BNP levels were low at baseline and did not
hange significantly immediately after stress testing or at 4 h
109, 119, and 124 pg/ml, respectively). In patients with
ild-to-moderate ischemia, median NT-pro-BNP levels
ere 158 pg/ml at baseline, exhibited a mild increase to 181
g/ml immediately after stress testing (p  0.01), and
emained at 181 pg/ml at 4 h. In patients with severe
schemia, median NT-pro-BNP levels were 302 pg/ml at
aseline, rose to 340 pg/ml immediately after stress testing
p  0.13), and reached 352 pg/ml at 4 h.
Levels of NT-pro-ANP are shown in Figure 3. Even in
atients without demonstrable inducible ischemia, median
T-pro-ANP levels rose from 680 pmol/l at baseline to 969
mol/l immediately after stress testing (p  0.0001), and
hen fell back down to 686 pmol/l by 4 h. Similarly, in
atients with mild-to-moderate ischemia, median NT-pro-
NP levels were 710 pmol/l at baseline, rose to 914 pmol/l
mmediately after stress testing (p  0.0001), and then fell
igure 1. Median B-type natriuretic peptide (BNP) levels in patients with
o (open circles), mild-to-moderate (black triangles), and severe (black
quares) ischemia, in whom samples were available at all three time points
baseline, immediately [Immed] after stress testing, and 4 h after stress
esting). The p values are for trend across ischemic categories at each time
oint. IQR  interquartile range; Mod  moderate.o 703 pmol/l at 4 h. In patients with severe ischemia,
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November 16, 2004:1988–95 Acute Changes in BNP With Myocardial Ischemiaedian NT-pro-ANP levels were 967 pmol/l at baseline,
ose to 1,215 pmol/l immediately after stress testing (p 
.009), and then fell to 854 pmol/l at 4 h.
Thus, the circulating levels of the three different natri-
retic peptides displayed different patterns in response to
xercise with and without ischemia. BNP levels differed
cross the ischemic categories at all three time points, and
here was a robust rise (25% of baseline levels) in ischemic
ut, importantly, not in non-ischemic patients. In contrast,
T-pro-BNP levels did not differ statistically across isch-
mic categories and the rise in ischemic patients was more
odest (10% of baseline levels). For NT-pro-ANP, a rise
as seen with exercise for all patients and did not differ
tatistically across ischemic categories (130 vs. 150 vs. 234
mol/l; p  0.16). Thus, the remainder of the analyses
ocuses on BNP levels.
radient of BNP levels at baseline and after stress
esting. The differences in BNP levels at baseline (43 vs. 62
s. 101 pg/ml in patients with none, mild-to-moderate, and
evere inducible ischemia, respectively) were statistically
ignificant (p  0.03). Moreover, this gradient remained
pparent after excluding patients with either a LV ejection
raction50% or a clinical history of heart failure: 43 versus
6 versus 97 pg/ml (p  0.08). Using a cut point of 80
g/ml, 30%, 38%, and 64% of patients with none, mild-to-
oderate, and severe inducible ischemia, respectively, had
levated levels (p  0.036). Again, this trend remained
pparent after excluding patients with LV dysfunction or a
igure 2. Median N-terminal fragment of BNP pro-hormone (NT-pro-
NP) levels in patients with no (open circles), mild-to-moderate (black
riangles), and severe (black squares) ischemia, in whom samples were
vailable at all three time points (baseline, immediately [Immed] after stress
esting, and 4 h after stress testing). The p values are for trend across
schemic categories at each time point. IQR  interquartile range; Mod 
oderate.linical history of heart failure: 26%, 31%, and 56% (p 
p
.14). In a multivariable logistic model, inducible ischemia
as more frequent among patients with an elevated baseline
NP compared with those with a baseline BNP 80 pg/ml
adjusted odds ratio [OR] 2.1, 95% confidence interval [CI]
.9 to 5.0). Excluding patients with LV dysfunction or a
linical history of heart failure, the adjusted OR was 1.7
95% CI 0.6 to 4.9).
igure 3. Median N-terminal fragment of ANP pro-hormone (NT-pro-
NP) levels in patients with no (open circles), mild-to-moderate (black
riangles), and severe (black squares) ischemia, in whom samples were
vailable at all three time points (baseline, immediately [Immed] after stress
esting, and 4 h after stress testing). The p values are for trend across
schemic categories at each time point. IQR  interquartile range; Mod 
oderate.
igure 4. Median post-stress test B-type natriuretic peptide (BNP) levels
ith interquartile ranges in patients with none, mild-to-moderate, and
evere ischemia, stratified into those with ejection fractions 50% (black
ars) and 50% (white bars). Numbers within each bar represent the
umber of patients in that group. The p values are for trend across ischemic
ategories (p 0.14 for patients with ejection fraction0.5; p 0.012 for
atients with ejection fraction 0.5.). ETT  exercise tolerance test; Mod
moderate.
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Acute Changes in BNP With Myocardial Ischemia November 16, 2004:1988–95The differences in circulating BNP levels between groups
ecame more pronounced after stress testing. Immediately
fter exercise, BNP levels were 49, 92, and 123 pg/ml,
espectively, in patients with none, mild-to-moderate, and
evere inducible ischemia (p  0.005). This gradient was
pparent both in patients with preserved LV ejection
ractions and in those with reduced LV ejection fractions
Fig. 4). Using a cut point of 80 pg/ml, 31%, 56%, and 71%
f patients with none, mild-to-moderate, and severe induc-
ble ischemia, respectively, had elevated levels (p  0.003).
his trend remained significant after excluding patients
ith impaired LV ejection fraction or a clinical history of
eart failure: 27%, 53%, and 67% (p  0.01).
hanges in circulating BNP levels. The median rise in
NP levels in response to exercise stress testing in patients
ategorized by myocardial ischemia is shown in Figure 5. Of
ote, seven patients had no evidence for inducible ischemia
n perfusion imaging, but had symptoms or electrocardio-
raphic changes sufficiently compelling as to lead to cardiac
atheterization. All of these patients were found to have
ritical coronary artery stenoses at coronary angiography and
re shown separately. Interestingly, the median increase in
atients with normal perfusion imaging but significant
oronary disease (9.6 pg/ml) was intermediate between the
ncrease seen in patients with mild-to-moderate ischemia on
erfusion imaging (14.2 pg/ml) and the change seen in
atients without ischemia (2.3 pg/ml).
After adjusting for differences in baseline characteristics
including age; gender; a history of hypertension, MI,
ABG, or CHF; use of beta-blockers, nitrates, angiotensin-
onverting enzyme inhibitors, angiotensin receptor blockers,
r digoxin; exercise duration and percent of maximal pre-
icted heart rate that was achieved; and low ejection
igure 5. Median changes in B-type natriuretic peptide (BNP) levels in re
o ischemia on scintigraphy but subsequently shown to have critical corona
ith severe ischemia (black bar). Numbers within each bar represent the
hange. The p value at the far right is for the trend across ischemic categ
mmediately; IQR  interquartile range; sx  symptoms.raction), mild-to-moderate ischemia was associated with a 08.5 pg/ml rise in BNP (p  0.021) and severe ischemia
as associated with a 28.5 pg/ml rise in BNP (p  0.015).
We explored the relationship between age and beta-
locker use and the rise of BNP in response to ischemia.
atients older than the median age (63 years) appeared to
anifest greater rises in BNP in response to ischemia (an
dditional 10.8 pg/ml, 95% CI 17.7 to 39.3 pg/ml) as did
atients taking beta-blockers (an additional 13.0 pg/ml,
5% CI 25.6 to 51.7 pg/ml), although neither interaction
eached statistical significance.
NP to predict ischemia. We created a multivariable logis-
ic regression model for inducible ischemia in which the
redictor variables were the components of the Duke treadmill
core (i.e., duration of exercise, presence and type of angina,
nd magnitude of ST-segment depression) plus post-stress test
NP as a categorical variable using a cutoff of 80 pg/ml. As can
e seen in Figure 6, an elevated BNP after stress testing was a
trong and independent predictor of ischemia, with an adjusted
R of 3.03 (95% CI 1.15 to 8.02, p 0.025). Reclassifying as
schemic those patients with no reversible defects on imaging
ut who were ultimately found to have significant CAD
evealed a more pronounced predictive ability of BNP, with an
djusted OR of 4.4 (95% CI 1.5 to 13.0, p  0.008). The
nclusion of additional covariates including age, gender, cardiac
isk factors (hypertension, diabetes, hypercholesterolemia, and
moking), and previous cardiac disease and procedures (angina,
ocumented significant coronary artery stenosis, previous MI,
ercutaneous coronary intervention, CABG, and CHF) did
ot change the predictive power of an elevated BNP (OR 3.8,
5% CI 1.1 to 14.0, p  0.04). Restricting the analyses to
atients with preserved LV systolic function, an elevated BNP
fter stress testing was an even stronger predictor of inducible
schemia with an adjusted OR of 5.9 (95% CI 1.2 to 28.9, p
se to exercise stress testing in patients with no ischemia (white bar), with
ase (light gray bar), with mild-to-moderate ischemia (dark gray bar), and
er of patients in that group. The p values by each bar are for the median
cath  cardiac catheterization; ECG  electrocardiographic; Immed spon
ry dise
numb.03).
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November 16, 2004:1988–95 Acute Changes in BNP With Myocardial IschemiaAn elevated post-stress test BNP, at a cut point of 80
g/ml, had a sensitivity of 60%, a specificity of 69%, and an
ccuracy of 64%. Similar results were obtained when using
he rise in BNP at a cut point of 10 pg/ml: the sensitivity
as 60%, the specificity was 69%, and the accuracy was 64%.
hereas the traditional predictors of myocardial ischemia
n stress testing, including male gender and all of the
omponents of the Duke treadmill score combined, had
nly moderate discriminatory capacity (c  0.74), by com-
ining the traditional factors and an elevated post-stress test
NP, discriminatory capacity was improved (c  0.82).
hen patients were categorized on the basis of how many
f the four risk factors were present (male gender, limiting
ngina, ST-segment depression, post-stress test BNP 80
g/ml), a stepwise and significant gradient of risk for
nducible myocardial ischemia was observed, ranging from
5% to 100% (Fig. 7, p  0.001).
ISCUSSION
nitial studies demonstrated the ability of BNP levels to
redict death and adverse cardiac events in the setting of
cute ST-segment elevation MI (3). We subsequently ex-
ended those observations across the spectrum of acute
oronary syndromes using samples obtained a median of
0 h from the onset of symptoms (5). In a later study, we
emonstrated the prognostic utility of BNP levels in sam-
les obtained within 24 h of presentation (6). We now
rovide evidence for an even more immediate and quanti-
ative link between acute transient myocardial ischemia and
he plasma concentration of BNP.
Our study has three major findings. First, patients with
reater ischemic burdens had higher baseline resting levels
f BNP, with qualitatively similar patterns for NT-pro-
NP and NT-pro-ANP. Second, circulating BNP levels
ose in response to exercise stress testing, and the magnitude
f that rise was proportional to the degree of inducible
schemia. The increase, however, was less pronounced for
T-pro-BNP and was not as specific for ischemia in regard
o NT-pro-ANP. Third, an elevated concentration of BNP
80 pg/ml) after exercise stress testing was a significant
igure 6. Point estimates and 95% confidence intervals (CI) for the odds
est B-type natriuretic peptide (BNP) 80 pg/ml. Adj  adjusted; ETTredictor of inducible ischemia, comparable to and inde- tendent of traditional parameters such as limiting angina
nd ST-segment depression. However, neither the absolute
alue nor the magnitude of rise of BNP post-stress testing
as sufficiently sensitive or specific by itself for the diagnosis
f inducible ischemia.
Whereas ANP is stored as pro-ANP and cleaved upon
elease into ANP and NT-pro-ANP, immunochromatog-
aphy studies suggest that the primary form of BNP stored
n the heart is the C-terminal BNP itself (9). This might
xplain why the absolute acute increases seen for BNP were
reater than that for NT-pro-BNP, an observation we have
lso made in the setting of heart failure (10). In addition,
he longer half-life of NT-pro-BNP compared with BNP (2
o 3 h vs. 18 min) leads to higher baseline circulating levels
f NT-pro-BNP. Therefore, small absolute increases in
T-pro-BNP may be harder to detect. The longer half-life
f NT-pro-BNP may also explain why the acute increases
een in NT-pro-BNP appeared to be more persistent. With
egard to NT-pro-ANP, although the acute changes we
bserved with exercise were robust, they were not as specific
or the presence of inducible ischemia. This may reflect the
act that ANP is released in response to tachycardia alone
11). This non-specific increase in circulating levels of ANP
n the setting of exercise may therefore mask all but the
ost severe changes resulting from ischemia (12).
In terms of BNP, several studies show that it appears to
e released in response to increased wall stress (13,14).
schemia can cause transient LV systolic and diastolic
ysfunction. We therefore speculate that individuals who
evelop ischemia during exercise also develop increases in
V end-diastolic wall tension, thereby triggering the release
f BNP from granules in the ventricles, atria, or both. Our
bservations support this pathophysiologic construct, as we
ound that the magnitude of the rise in BNP levels after
tress testing was related to the degree of inducible ischemia.
ven after adjusting for differences in demographics, cardiac
istory, medications, exercise performance, and ejection
raction, the degree of myocardial ischemia was indepen-
ently associated with the magnitude of increase in BNP
evels. We also found that baseline BNP levels before stress
(OR) for the components of the Duke Treadmill Score and a post-stress
rcise tolerance test.ratioesting were elevated in patients who subsequently devel-
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hen restricted to patients with a normal ejection fraction
nd no clinical history of heart failure. This observation may
eflect the effects of chronic or repetitive ischemia on BNP
ynthesis and release.
Our findings are supported by data from several other
tudies. The Heart and Soul Study found that patients with
aseline BNP levels 105 pg/ml (a cut point similar to the
aseline levels seen in our patients with severe inducible
schemia) were at a two-fold increased risk of having a new
all motion abnormality on exercise echocardiography (15).
n terms of acute changes in circulating BNP levels, in a
tudy of 70 individuals who were categorized on the basis of
ngiography, those with documented CAD had higher
evels of BNP during exercise than those without (12). In a
ecent study of patients with angiographically confirmed
AD, the average increase in BNP with exercise across the
ntire study population was 18 pg/ml (16). It has also been
hown that BNP levels rise after coronary angioplasty, but
ot coronary angiography, an observation ascribed to myo-
ardial ischemia due to transient coronary occlusion with
alloon inflation (17).
Although larger than many of the previous studies, our
tudy is still relatively small. However, it was an unselected
opulation that reflected typical patients presenting for
tress testing. We relied on nuclear imaging to quantify the
egree of ischemia. This remains an imperfect gold stan-
ard. Nonetheless, we think it superior to angiography
lone, which can verify the presence of coronary atheroscle-
osis but cannot demonstrate inducible ischemia. The mag-
itude in rise of BNP was relatively small, and the inter-
uartile ranges were wide. However, by design, the duration
f significant ischemia during stress testing is brief. More-
ver, other factors, including heart failure, can contribute to
n elevated BNP. Our goal was not to demonstrate the
igure 7. Proportion with inducible ischemia among patients categorized
y the number of risk factors (male gender, limiting angina, ST-segment
epression, post-stress test B-type natriuretic peptide level 80 pg/ml).
umbers within each bar represent the number of patients in that group.
he p value is for trend across categories.tility of a “stress BNP,” but rather to study the releaseatterns of cardiac natriuretic peptides in response to
ransient myocardial ischemia. The ability of BNP levels to
dd to the diagnostic utility of stress testing needs to be
onfirmed in additional studies.
In summary, we found that transient myocardial ischemia
as associated with an immediate increase in circulating
NP levels and, to a lesser extent, NT-pro-BNP levels, and
hat the degree of rise was proportional to the severity of
schemia. These findings confirm an important pathophys-
ologic link between the severity of an acute ischemic insult
nd the level of circulating BNP, and thus support the
ncorporation of BNP into multimarker strategies for risk
tratification to gain insight into ventricular dysfunction
ssociated with myocardial ischemia (18).
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